Leerink Partnrs Has Negative Outlook for Sanofi Q4 Earnings

Sanofi (NASDAQ:SNY) – Equities research analysts at Leerink Partnrs decreased their Q4 2024 EPS estimates for Sanofi in a research note issued on Sunday, October 27th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $0.83 per share for the quarter, down from their previous forecast of $0.94. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2025 earnings at $4.67 EPS.

SNY has been the topic of several other research reports. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of Sanofi stock opened at $53.45 on Tuesday. The company has a market capitalization of $135.65 billion, a price-to-earnings ratio of 27.27, a PEG ratio of 1.55 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock’s 50-day simple moving average is $56.02 and its 200-day simple moving average is $51.91. Sanofi has a 52 week low of $45.00 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the company earned $2.55 EPS. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis.

Institutional Investors Weigh In On Sanofi

Several large investors have recently bought and sold shares of SNY. Maia Wealth LLC bought a new position in shares of Sanofi in the 3rd quarter valued at about $272,000. Harvest Portfolios Group Inc. lifted its stake in shares of Sanofi by 4.2% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 37,200 shares of the company’s stock valued at $2,144,000 after purchasing an additional 1,500 shares during the last quarter. HF Advisory Group LLC increased its position in shares of Sanofi by 5.5% during the 3rd quarter. HF Advisory Group LLC now owns 28,763 shares of the company’s stock valued at $1,658,000 after purchasing an additional 1,487 shares during the last quarter. PDS Planning Inc increased its position in shares of Sanofi by 3.1% during the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the last quarter. Finally, Garrison Asset Management LLC purchased a new stake in Sanofi during the 3rd quarter valued at $231,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.